About Guardant Health, Inc.
https://guardanthealth.comGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
CEO
Helmy Eltoukhy
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 198
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 21
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:11.91M
Value:$1.29B
BLACKROCK, INC.
Shares:11.43M
Value:$1.24B
BLACKROCK INC.
Shares:11.24M
Value:$1.22B
Summary
Showing Top 3 of 462
About Guardant Health, Inc.
https://guardanthealth.comGuardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $265.2M ▲ | $270.6M ▲ | $-92.72M ▲ | -34.96% ▲ | $-0.74 ▲ | $-82.24M ▲ |
| Q2-2025 | $232.09M ▲ | $257.3M ▲ | $-99.9M ▼ | -43.04% ▲ | $-0.8 ▼ | $-88.84M ▼ |
| Q1-2025 | $203.47M ▲ | $239.79M ▼ | $-95.16M ▲ | -46.77% ▲ | $-0.77 ▲ | $-83.84M ▲ |
| Q4-2024 | $201.81M ▲ | $250.19M ▲ | $-111.01M ▼ | -55% ▲ | $-0.9 ▼ | $-99.19M ▼ |
| Q3-2024 | $191.48M | $234.31M | $-107.75M | -56.28% | $-0.88 | $-96.48M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $580.01M ▼ | $1.28B ▼ | $1.63B ▼ | $-354.47M ▼ |
| Q2-2025 | $629.14M ▼ | $1.33B ▼ | $1.64B ▲ | $-305.48M ▼ |
| Q1-2025 | $698.57M ▼ | $1.34B ▼ | $1.6B ▼ | $-250.79M ▼ |
| Q4-2024 | $839.98M ▼ | $1.49B ▼ | $1.63B ▲ | $-139.65M ▼ |
| Q3-2024 | $999.07M | $1.54B | $1.6B | $-60.1M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-92.72M ▲ | $-35.41M ▲ | $-14.35M ▼ | $4.33M ▲ | $-45.97M ▲ | $-45.76M ▲ |
| Q2-2025 | $-99.9M ▼ | $-60.28M ▲ | $-10.65M ▼ | $1.62M ▲ | $-68.37M ▼ | $-65.93M ▲ |
| Q1-2025 | $-95.16M ▲ | $-62.69M ▲ | $302.86M ▲ | $-66.85M ▼ | $174.1M ▲ | $-67.15M ▲ |
| Q4-2024 | $-111.01M ▼ | $-64.51M ▼ | $10.53M ▲ | $-2.94M ▼ | $-58.61M ▲ | $-83.39M ▼ |
| Q3-2024 | $-107.75M | $-51.06M | $-294.83M | $-2.88M | $-346.87M | $-55.26M |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $10.00M ▲ | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 UNITED STATES | $190.00M ▲ | $190.00M ▲ | $220.00M ▲ | $250.00M ▲ |
CEO
Helmy Eltoukhy
Compensation Summary
(Year 2023)
ETFs Holding This Stock
Summary
Showing Top 3 of 198
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 21
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:11.91M
Value:$1.29B
BLACKROCK, INC.
Shares:11.43M
Value:$1.24B
BLACKROCK INC.
Shares:11.24M
Value:$1.22B
Summary
Showing Top 3 of 462